ES2103255T3 - Derivados de la purina como inhibidores de interleuquina-1. - Google Patents

Derivados de la purina como inhibidores de interleuquina-1.

Info

Publication number
ES2103255T3
ES2103255T3 ES87119377T ES87119377T ES2103255T3 ES 2103255 T3 ES2103255 T3 ES 2103255T3 ES 87119377 T ES87119377 T ES 87119377T ES 87119377 T ES87119377 T ES 87119377T ES 2103255 T3 ES2103255 T3 ES 2103255T3
Authority
ES
Spain
Prior art keywords
interleukin
inhibitors
purine derivatives
interleukina
enmamiferos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87119377T
Other languages
English (en)
Inventor
Gerald L Mandell
Gail W Sullivan
William J Novick Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
Aventis Pharmaceuticals Inc
University of Virginia UVA
Original Assignee
University of Virginia UVA
Hoechst Marion Roussel Inc
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia UVA, Hoechst Marion Roussel Inc, University of Virginia Patent Foundation filed Critical University of Virginia UVA
Application granted granted Critical
Publication of ES2103255T3 publication Critical patent/ES2103255T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA FAMILIA DE COMPUESTOS EFECTIVOS PARA INHIBIR LA ACTIVIDAD DE INTERLEUKINA-1 SE IDENTIFICA COMO (I). LA INHIBICION DE IL-1 ENMAMIFEROS ESTA IMPLICADA EN EL ALIVIO DE UNA AMPLIA VARIEDAD DE ENFERMEDADES.
ES87119377T 1986-12-31 1987-12-30 Derivados de la purina como inhibidores de interleuquina-1. Expired - Lifetime ES2103255T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94790586A 1986-12-31 1986-12-31

Publications (1)

Publication Number Publication Date
ES2103255T3 true ES2103255T3 (es) 1997-09-16

Family

ID=25486973

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87119377T Expired - Lifetime ES2103255T3 (es) 1986-12-31 1987-12-30 Derivados de la purina como inhibidores de interleuquina-1.

Country Status (14)

Country Link
EP (1) EP0279079B1 (es)
JP (1) JP2507012B2 (es)
KR (1) KR960015726B1 (es)
AT (1) ATE151290T1 (es)
AU (1) AU668982B2 (es)
CA (1) CA1313137C (es)
DE (1) DE3752048T2 (es)
DK (1) DK482088A (es)
ES (1) ES2103255T3 (es)
GR (1) GR3024054T3 (es)
IE (1) IE873554L (es)
IL (7) IL106854A (es)
WO (1) WO1988004928A1 (es)
ZA (1) ZA879754B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272153A (en) * 1986-12-31 1993-12-21 Hoechst-Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5196429A (en) * 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5196430A (en) * 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
WO1990015534A1 (en) * 1989-06-13 1990-12-27 Smithkline Beecham Corporation Monokine activity interference
DD298051A5 (de) * 1989-08-16 1992-02-06 ��@���������@�������k�� Verfahren zur herstellung eines therapeutischen agens zur behandlung von verdauungskrankheiten
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
EP0490181A1 (en) * 1990-11-30 1992-06-17 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for preparation of a medicament having immunosuppressing activity
IL100194A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
AU664189B2 (en) * 1991-05-24 1995-11-09 Fred Hutchinson Cancer Research Center Modulation of cellular response to external stimuli
EP0518263A1 (en) * 1991-06-10 1992-12-16 Hoechst-Roussel Pharmaceuticals Incorporated Micropellets and a process for their manufacture
WO1993003728A1 (en) * 1991-08-27 1993-03-04 Temple University Of The Commonwealth System Of Xanthine suppression of antigen activation of t- or b-cells
WO1993008819A1 (en) * 1991-10-31 1993-05-13 The Victoria University Of Manchester Treatment of neurological conditions by an interleukin-1 inhibiting compound
AU3539795A (en) * 1994-08-25 1996-03-14 Medical University Of South Carolina Methods of treating cold symptoms using pentoxifylline
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
JP3830115B2 (ja) * 1997-10-06 2006-10-04 シャープ株式会社 液晶表示素子
TW561297B (en) * 1997-11-25 2003-11-11 Toshiba Corp Electrode wiring board subjected to counter measure against static electricity and display device using the same
JP3019053B2 (ja) * 1997-12-25 2000-03-13 日本電気株式会社 液晶表示装置及びその製造方法
EP3199203B1 (en) 2008-02-29 2020-02-05 Concert Pharmaceuticals Inc. Substituted xanthine derivatives
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
CA2771331A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP2611807A2 (en) 2010-09-01 2013-07-10 Concert Pharmaceuticals Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)dione
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US9328113B2 (en) 2012-04-13 2016-05-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2013159006A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2967632D1 (en) * 1978-04-22 1986-12-04 Beecham Wuelfing Gmbh & Co Kg Use of a xanthine derivate in the manufacture of a medicament
US4567183A (en) * 1983-03-11 1986-01-28 Analgesic Associates Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
GB8418430D0 (en) * 1984-07-19 1984-08-22 Beecham Wuelfing Gmbh & Co Kg Treatment

Also Published As

Publication number Publication date
IL84934A (en) 1994-08-26
KR890700347A (ko) 1989-04-24
IL106859A (en) 1996-10-16
JP2507012B2 (ja) 1996-06-12
IL106854A (en) 1996-05-14
DK482088D0 (da) 1988-08-30
IL100536A (en) 1994-05-30
DE3752048T2 (de) 1997-10-02
AU637542B2 (en) 1993-05-27
DK482088A (da) 1988-10-28
JPH02501829A (ja) 1990-06-21
AU1150588A (en) 1988-07-27
KR960015726B1 (ko) 1996-11-20
IL106861A (en) 1997-02-18
EP0279079A3 (en) 1990-06-13
WO1988004928A1 (en) 1988-07-14
IL100535A (en) 1994-05-30
AU4602793A (en) 1993-11-18
AU1291892A (en) 1992-05-14
IL100533A (en) 1994-05-30
ATE151290T1 (de) 1997-04-15
GR3024054T3 (en) 1997-10-31
AU668982B2 (en) 1996-05-23
AU619732B2 (en) 1992-02-06
CA1313137C (en) 1993-01-26
DE3752048D1 (de) 1997-05-15
EP0279079B1 (en) 1997-04-09
ZA879754B (en) 1989-07-26
EP0279079A2 (en) 1988-08-24
IE873554L (en) 1988-06-30

Similar Documents

Publication Publication Date Title
ES2103255T3 (es) Derivados de la purina como inhibidores de interleuquina-1.
ES8703876A1 (es) Un procedimiento para la preparacion de derivados de purina.
ES2122076T3 (es) Derivados de nor-acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
ES541411A0 (es) Un procedimiento para desinfectar un substrato
ES2159851T3 (es) Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa.
ES2051675T3 (es) Inhibidores de protorfirinogeno y su uso en composiciones para detectar y tratar tumores.
ES2131830T3 (es) Benzamidinas sustituidas, su preparacion y uso como medicamentos.
ES550241A0 (es) Procedimiento para preparar nuevos derivados imidazo
ES556493A0 (es) Procedimiento para preparar nuevos derivados imidazo.
IT1122090B (it) Procedimento di denitrificazione delle acque per via biologica
ES2001003A4 (es) Metodo para preparar polimeros de sulfometil-poliacrilamidas.
ES2068216T3 (es) Compuestos de tienotriazolodiazepina y usos farmaceuticos de los mismos.
ES2056983T3 (es) Compuestos para inhibir la biosintesis de metabolitos de acido araquidonico derivados de lipoxigenasa.
ATE152356T1 (de) Topisches präparat zur besseren heilung von herpesverletzungen
FI875278A7 (fi) Malonihapon johdannaisyhdisteiden käyttö satosaannon lisäämiseksi.
ES549804A0 (es) Procedimiento para preparar nuevos derivados imidazo
AR225031A1 (es) Compuesto de 1,1-dioxido de acido penicilanico,sin actividad terapeutica,utiles como intermediarios para elaborar inhibidores de beta-lactamasa y procedimiento para producir dichos inhibidores de beta-lactamasa,partiendo de dichos intermediarios
AR004330A1 (es) Uso de inhibidores de colinesterasa en el tratamiento de xerostomia
ES8504794A1 (es) Un procedimiento para la preparacion de una quinazolina
ATE72430T1 (de) Dopamin-beta-hydroxylase-inhibitoren.
MX9204528A (es) 0etodo para tratar el sindrome premenstrual mediante administracion de un inhibidor de la enzima de conversion de angiotensina.
ES8502678A1 (es) Un procedimiento de preparar disfenilazometinas que llevan una cadena esterificada
ES8307204A1 (es) "un procedimiento para la preparacion de una difenilamina".
IT1213571B (it) Procedimento per formare i ranghi di maglia di articoli di calzetteria.
ES2059392T3 (es) Etodolac para la inhibicion de la anquilosis de las articulaciones.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 279079

Country of ref document: ES